Agoracom Blog Home

Posts Tagged ‘HLS Therapeutics’

VIDEO – Valeo Pharma (VPH: CSE) (VPHIF: OTCQB) Hits Record Annual Revenues Of $13.6 MILLION … Targeting $150 MILLION By 2025

Posted by AGORACOM-JC at 7:30 PM on Sunday, March 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

2021 HIGHLIGHTS:

  • $13.6 MILLION              Record Annual Revenues Up 81% Over 2020
  • $9.1 MILLION                Record 2nd Half Revenues
  • $4 MILLION                   Record Annual Gross Profit Up 186% over 2020
  • $43 MILLION                 Record Financing Through 2021 / Subsequent To Year End 

If you think these numbers are impressive, consider the fact that 3 important factors to their business were only partially launched in fiscal 2021, namely:

●       Each of their transformational products were staggered released, now fully released

●       Insurance & Government reimbursement approvals were staggered, now nearly 100%

●       Corporate Structuring related to staffing and distribution was ramping, now 100%

$150 MILLION REVENUE TARGET BY 2025

Despite the ramp up and staggered milestones, this translated into $9.1M in second half revenue for $VPH, which we would easily extrapolate at 150% – 200% for all of 2022 or ~ $23M – $27M in revenue … but that is just our own back of the napkin math with imperfect information.

If you want to hear it straight from the horses’ mouth $VPH believes it can achieve $150M in revenue by 2025.

Commenting on the fourth quarter and record year-end 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer stated:

“As expected, the significant increase in Q4-2021 revenues and record annual revenues resulted mainly from the addition of the new products launched during the year. Valeo is now very well positioned to leverage its new corporate and commercial infrastructure to capitalize on the market potential of its existing product portfolio,”

 Sit back, relax and watch this powerful interview with CEO Steve Saviuk.

VIDEO – Valeo Pharma Immune Booster Now Available In ~300 Stores Under Loblaws Banner, Another Step Closer to 2025 Revenue Target of $160M

Posted by AGORACOM-JC at 1:40 PM on Thursday, January 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

The company released stellar a Q3 with the following highlights:    

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

But wait, there’s more…

The company announced that Hesperco™ Is Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted For Publication.

  • Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
    • Loblaws
    • Dominion,
    • Zehrs,
    • Fortinio’s,
    • Your Independent Grocer and Superstore

Steve Saviuk , CEO commented,

We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”

But wait, there’s more…

The company Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec.

Now sit back, relax and watch this powerful interview with Valeo Pharma.

VIDEO – Valeo Pharma Obtains Public Reimbursement For Asthma Drugs In Quebec and Nova Scotia, Another Step Closer to 2025 Revenue Target of $160M

Posted by AGORACOM-JC at 4:38 PM on Friday, December 17th, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.   

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.    

Q3 Highlights:   

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

Clearly, Valeo Pharma is firing on all cylinders. This is evident by the company’s recent announcement that they Obtained Public Reimbursement For Enerzair® Breezhaler® And Atectura® Breezhaler® In Quebec And Nova Scotia.

  • Public reimbursement now includes Alberta , Quebec and Nova Scotia , representing approximately 37% of the Canadian population.
  • More than 90% private insurance coverage across Canada

Frederic Fasano, Valeo’s President and Chief Operating Officer commented,

“We are pleased to be reporting today the addition of Quebec and Nova Scotia to join Alberta on the list of provincial public coverage secured for both asthma medications. Public Reimbursement access makes a meaningful impact for asthma patients left with no coverage so far, and also simplify health care providers procedures to provide access of both medications to their patients. Enerzair and Atectura are innovative asthma therapies that are helping make asthma control a more attainable goal for Canadians asthma patients”.

But wait, there’s more…

The company just Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec.

Now sit back, relax and watch this powerful interview with Valeo Pharma.

VIDEO – Valeo Pharma Agreement Supports $30M Annual Revenue Target From Blood Thinner Product Alone

Posted by AGORACOM-JC at 4:12 PM on Wednesday, October 13th, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.  

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.   

Q3 Highlights:  

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

In today’s announcement, Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada.

Highlighted by the following;

  • 2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products
  • The 2 multi-year product listings commenced on October 1, 2021
  • The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario

The agreement above supports $30M annual revenue target From blood thinner product alone!

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

VIDEO – Valeo Pharma (VPH:CSE) Reported Record Q3-21 Revenue of $5.7 million, up 280% over Q3-20

Posted by AGORACOM-JC at 5:22 PM on Thursday, September 23rd, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

The company recently released Q3 results and highlights:

·  Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.

·  Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.

·  Record 9 months revenues at $10.2 million , up 94%.

·  Private and public reimbursement coverage expanding for Redesca®

·  New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

VIDEO – Valeo Pharma (VPH:CSE) Reported Record Q2 Revenue of $2.65M, CEO Expects Q3 To Increase More Than 50%

Posted by AGORACOM-JC at 12:23 PM on Monday, July 5th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

The smile on CEO Steve Saviuk says it all. The company recently released Q2 results and highlights:

  • Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter
  • Q3-21 revenues expected to increase by more than 50% over Q2-21
  • Redesca (blood thinner) launched in late Q2-21
  • Commercial shipments of the company’s asthma drugs commenced following national respiratory sales force deployment
  • Closed upsized $6.645 million debenture placement
  • Closed $11.5 million bought deal

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

AGORACOM Small Cap 60: Valeo $VPH $VPHIF Blood Clot Prevention Drug Approved By Ont Drug Plan, Other Provinces To Follow Suit $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 10:43 AM on Friday, May 7th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

VIDEO – Valeo Pharma $VPH $VPHIF Drug Projected To Add $30M / Year Revenue Gets Ontario Public Drug Coverage $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:22 PM on Thursday, April 29th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • 2020 net revenues of $7.5 million
  • 2021 is expected to double to $15 million
  • Commercializing Novartis Asthma Therapies In Canada
  • Closed $6.6 Million Financing With Insiders Taking ~ 40% 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-20% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $40,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-20% market share without one hell of a fight.  Saviuk agreed and gave the following 3 reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

More than just lip service, $VPH just announced that Redesca is now listed on the Ontario Public Drug Program, which means the government will cover its costs for all public use.  Moreover, $VPH expects additional Provinces to follow.   

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

Valeo Pharma $VPH $VPHIF Announces Commercial Launch of Redesca™ and Redesca HP™ $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:12 AM on Thursday, April 15th, 2021
  • Shipments have commenced across Canada
  • National sales coverage in full deployment through a dedicated key account managers team
  • Private and public reimbursement activities on target.

MONTREAL , April 15, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has commenced commercial shipments across Canada of Redesca™ and Redesca HP™, its low molecular weight heparin (“LMWH”) biosimilar.

“Making Redesca™ widely available in Canada is a key element  of our commercialization plans and we are pleased to have done so ahead of target. We continue to work on expanding both public and private reimbursement coverage across all provinces”, said Steve Saviuk , Valeo’s Chief Executive Officer. ” Redesca™ is the first of three transformative products that Valeo is launching this year and it will be accretive to second quarter revenues with increasing sales growth in the quarters to come.”

Commenting on the Redesca™ commercial launch, Frederic Fasano , Valeo’s President and Chief Operating Officer said; “Redesca™ is now available for patients, both at retail pharmacies and hospitals. The combination of a strong and proven safety profile, a complete product line, a robust supply chain on top of material savings to payers, contributes to the compelling Redesca™ value proposition for patients, clinicians and healthcare systems. We look forward to realizing Redesca™’s full potential over the coming quarters”.

In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against COVID-19. The World Health Organization’s (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.

About Redesca®, Redesca HP®

Redesca® is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca® has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Valeo Pharma $VPH $VPHIF Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:44 AM on Wednesday, April 14th, 2021
  • Announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000
  • Valeo insiders participate for $2.6 million

MONTREAL , April 14, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000 (the “Offering”).

Each Debenture Unit will consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture”) and 200 Class “A” share purchase warrants (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Class “A” Share of the Company (each, a “Share”) at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the “Closing Date”). The Debentures will mature at the latest 9 months after the closing and will bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.

“We are appreciative of the continued support from insiders and investors close to the Company  in this placement”, said Steve Saviuk , Valeo’s Chief Executive Officer. “This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair® Breezhaler®, Atectura® Breezhaler® and Redesca™. Commercialized through two distinct sales forces, these products are key drivers to our growth over the coming years”.

The net proceeds of the Offering will be used for working capital and general corporate purposes.

Closing of the Private Placement is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the CSE. The Company may pay finder’s fees on the non-insider portion of the Private Placement, in compliance with applicable securities laws. All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.

The issuance of Convertible Debentures to the insiders will be considered related party transactions within the meaning of Multilateral Instrument 61-101 (“MI 61-101”). The Company intends to rely on the exemptions from the requirements of MI 61-101 in respect of any Insider Participation.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurology, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.